Covid19
Conditions
Keywords
MMR vaccine, Respiratory failure,
Brief summary
Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness
Interventions
Measles mumps Rubella vaccine is a weak attenuated life vaccine
DRUGPlacebos
0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Sponsors
Kasr El Aini Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-50 years old * Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact
Exclusion criteria
* acute severe illness * recent receipt of a blood product * history of thrombocytopenia * Pregnant females * any chronic medical condition * Any participant receiving any immune suppressive medication * Immunocompromised staff * Participants who have egg allergy * Participants who care for immune compromised hosts * Participants who test positive for COVID-19 serology prior to randomization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19 disease incidence | Time Frame: Measured over the 6 months following randomization | Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SARS-CoV-2 pneumonia | Time Frame: Measured over the 6 months following randomization | Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test |
| Critical care admission duration with SARS-CoV-2 | Time Frame: Measured over the 6 months following randomization | Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test |
| Oxygen therapy with SARS-CoV-2 | Time Frame: Measured over the 6 months following randomization | Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test |
Countries
Egypt
Outcome results
None listed